Scandinavian Tobacco Group A/S

Company Announcement No. 3/2021

Copenhagen, 18 January 2021

Transactions in connection with share buy-back programme

On 28 August 2020, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 300 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme.

The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 26 February 2021.

The following transactions have been executed from 11 January to 15 January 2021:

	Number of shares	Average purchase price, DKK	Transaction value, DKK
Accumulated, last announcement	2,148,123		207,690,425
11 January 2021	30,000	110.91	3,327,435
12 January 2021	43,911	110.22	4,839,971
13 January 2021	22,000	110.24	2,425,306
14 January 2021	22,000	110.78	2,437,072
15 January 2021	22,000	111.88	2,461,433
Accumulated under the program	2,288,034		223,181,642

A detailed overview of transactions during the period 11 January – 15 January 2021 is attached to this announcement.

Following the above transactions STG owns a total of 2,564,542 treasury shares, corresponding to 2.56% of the total share capital.

For further information, please contact:
Investors : Torben Sand, Head of Investor Relations,
phone: +45 5084 7222 or torben.sand@st-group.com

Media : Simon Mehl Augustesen, Director of Group Communications,
phone: +1 484-379-8725 or simon.augustesen@st-group.com

Attachments

• Company Announcement no 3 2021
• 15 JAN 2021 PUBLIC_SBB_SCANDINAVIAN TOBACCO GROUP

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.